NCT00747123 2024-10-03
A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma
Celgene
Phase 2 Completed
Celgene
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Indiana University